Martin Edelman, MD
Inaugural Chair of the Department of Medical Oncology at the Lewis Katz School of Medicine (LKSOM) at Temple University
For Fox Chase Cancer Center and the larger Temple Health community, the appointment of Martin Edelman, MD, is an exciting new opportunity to collaborate and integrate cancer care within these two institutions. Dr. Edelman is now the inaugural Chair of the Department of Medical Oncology at the Lewis Katz School of Medicine (LKSOM) at Temple University and will continue to serve as the Chair of the Department of Hematology/Oncology.
In his new role, Dr. Edelman will develop the department's strategic vision, considering the tripartite mission of LKSOM and Temple University Health System: clinical care, education, and research to advance patient care and cultivate the next generation of physicians and other healthcare professionals.
Dr. Edelman joined Fox Chase in 2017 and will continue in his present roles there and continue to hold the G. Morris Dorrance Jr. Chair in Medical Oncology.
Dr. Edelman’s skill in leading all phases of clinical, scientific, and administrative activities will be the engine for clinical research, and translational research programs, as well as aligning emerging national trends with the delivery of care. Dr. Edelman will continue to oversee faculty responsible for recruiting, managing, and retaining diverse professionals and provide ongoing mentorship to help steward faculty members' careers, promoting a culture of scholarship. He also serves as Associate Cancer Center Director for Clinical Research Integration at Fox Chase Cancer Center. In this role, he oversees the integration of the clinical trials efforts in cancer across the health system, with the goal of assuring access to cutting edge trials to the entire population served by TUHS.
A nationally recognized lung cancer treatment and research expert, Dr. Edelman has leadership positions in the National Clinical Trials Network and other national and international organizations focused on lung cancer. His research is focused on developing new agents and biomarkers to personalize lung cancer therapy, and the multimodality treatment of thoracic cancers. Truly a clinician of exceptional vision, innovation, and leadership.
Sukhmani K. Padda, MD
Vice Chair of Medical Oncology at the Fox Chase Cancer Center at Temple University Hospital
Sukhmani K. Padda, MD, Professor and Vice Chair of Medical Oncology at the Fox Chase Cancer Center at Temple University Hospital, comes from Cedars-Sinai Medical Center in Los Angeles, where she served as Director of Thoracic Medical Oncology and an Associate Professor of Medicine. Dr. Padda focuses on early-phase trials examining targeted therapeutics in genomic subsets of non-small cell lung cancer and rare thoracic tumors, including neuroendocrine and thymic malignancies. She is active in the National Clinical Trials Network and leads national studies investigating novel therapeutics in lung cancer.
Before Cedars-Sinai Medical Center, Dr. Padda spent several years as an Assistant Professor of Medicine and also served as Phase 1 Clinical Research Group Leader at Stanford University. She is a member of the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer, the North American Neuroendocrine Tumor Society, and the International Thymic Malignancy Interest Group. Over her career, Dr. Padda has earned multiple honors, including the Department of Medicine Teaching Award from Stanford University and the Stanford Cancer Institute Cancer Innovation Award. She also recently completed the ASCO Leadership Development Program and currently serves on the ASCO government committee.
Dr. Padda reviews for various journals, including the Journal of Thoracic Oncology, Lancet Oncology, Lung Cancer, and the Journal of Clinical Oncology. She has also published over 50 peer-reviewed journal articles and numerous reviews, editorials, and book chapters. Dr. Padda will enhance the commitment of Temple and Fox Chase's commitment to discovering and delivering novel cancer treatments.